ClearPoint Neuro (CLPT) Competitors $10.53 -0.42 (-3.84%) Closing price 04:00 PM EasternExtended Trading$10.53 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLPT vs. MDXG, PLSE, INMD, IRMD, EMBC, TNDM, KMTS, BBNX, AXGN, and SIBNShould you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include MiMedx Group (MDXG), Pulse Biosciences (PLSE), InMode (INMD), iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), Kestra Medical Technologies (KMTS), Beta Bionics (BBNX), AxoGen (AXGN), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. ClearPoint Neuro vs. Its Competitors MiMedx Group Pulse Biosciences InMode iRadimed Embecta Tandem Diabetes Care Kestra Medical Technologies Beta Bionics AxoGen SiBone ClearPoint Neuro (NASDAQ:CLPT) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings. Which has more risk and volatility, CLPT or MDXG? ClearPoint Neuro has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Do analysts prefer CLPT or MDXG? ClearPoint Neuro currently has a consensus price target of $19.67, indicating a potential upside of 86.77%. MiMedx Group has a consensus price target of $12.00, indicating a potential upside of 74.17%. Given ClearPoint Neuro's higher possible upside, equities research analysts clearly believe ClearPoint Neuro is more favorable than MiMedx Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ClearPoint Neuro 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00MiMedx Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CLPT or MDXG more profitable? MiMedx Group has a net margin of 8.84% compared to ClearPoint Neuro's net margin of -66.15%. MiMedx Group's return on equity of 23.03% beat ClearPoint Neuro's return on equity.Company Net Margins Return on Equity Return on Assets ClearPoint Neuro-66.15% -94.44% -51.58% MiMedx Group 8.84%23.03%17.09% Which has better valuation and earnings, CLPT or MDXG? MiMedx Group has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClearPoint Neuro$33.59M8.91-$18.91M-$0.81-13.00MiMedx Group$363.77M2.80$42.42M$0.2132.81 Does the media favor CLPT or MDXG? In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 3 articles in the media. MiMedx Group's average media sentiment score of 1.44 beat ClearPoint Neuro's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MiMedx Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in CLPT or MDXG? 30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 7.0% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 1.7% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryMiMedx Group beats ClearPoint Neuro on 10 of the 14 factors compared between the two stocks. Get ClearPoint Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLPT vs. The Competition Export to ExcelMetricClearPoint NeuroMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.34M$6.75B$5.78B$10.04BDividend YieldN/A1.14%5.27%4.52%P/E Ratio-13.0025.8875.5726.08Price / Sales8.91144.80516.51171.66Price / CashN/A22.1637.2059.76Price / Book11.454.9311.536.20Net Income-$18.91M$178.27M$3.29B$270.65M7 Day Performance2.73%-0.09%0.44%2.77%1 Month Performance-2.68%3.10%10.84%8.83%1 Year Performance-12.69%8.02%61.62%27.49% ClearPoint Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLPTClearPoint Neuro1.3598 of 5 stars$10.53-3.8%$19.67+86.8%-7.5%$299.34M$33.59M-13.00110MDXGMiMedx Group3.1724 of 5 stars$7.10-1.1%$12.00+69.0%+15.8%$1.05B$348.88M33.81870Positive NewsPLSEPulse Biosciences3.9471 of 5 stars$15.54-0.1%$22.00+41.6%-14.8%$1.05B$700K-14.80140Positive NewsINMDInMode3.5437 of 5 stars$14.94+0.1%$18.04+20.8%-2.9%$944.34M$394.82M6.05480News CoveragePositive NewsIRMDiRadimed4.7964 of 5 stars$72.44-0.8%$72.00-0.6%+59.8%$921.44M$73.24M44.72110Positive NewsEMBCEmbecta4.6427 of 5 stars$14.48-0.1%$19.00+31.2%-0.6%$846.86M$1.12B10.132,100Positive NewsTNDMTandem Diabetes Care4.5902 of 5 stars$12.51+6.1%$22.47+79.6%-70.3%$845.29M$940.20M-4.052,650News CoveragePositive NewsAnalyst ForecastShort Interest ↓KMTSKestra Medical Technologies1.7275 of 5 stars$16.14-8.9%$27.33+69.4%N/A$828.77M$59.81M0.00300News CoverageInsider TradeBBNXBeta BionicsN/A$18.84+0.7%$22.56+19.7%N/A$818.98M$65.12M0.00294News CoverageInsider TradeAXGNAxoGen2.9046 of 5 stars$16.14-0.5%$26.00+61.1%+26.1%$742.64M$187.34M-161.38450Positive NewsShort Interest ↓SIBNSiBone3.993 of 5 stars$16.67+0.3%$23.67+42.0%+6.7%$719.16M$167.18M-29.77350Positive News Related Companies and Tools Related Companies MiMedx Group Competitors Pulse Biosciences Competitors InMode Competitors iRadimed Competitors Embecta Competitors Tandem Diabetes Care Competitors Kestra Medical Technologies Competitors Beta Bionics Competitors AxoGen Competitors SiBone Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLPT) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLPT Stock Alerts